These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29860436)

  • 1. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
    Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
    Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.
    Negoescu DM; Enns EA; Swanhorst B; Baumgartner B; Campbell JP; Osterman MT; Papamichael K; Cheifetz AS; Vaughn BP
    Inflamm Bowel Dis; 2020 Jan; 26(1):103-111. PubMed ID: 31184366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
    Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
    J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.
    Queiroz NSF; Teixeira FV; Parra RS; Kotze PG
    Arq Gastroenterol; 2020; 57(4):507-510. PubMed ID: 33331484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab in young paediatric IBD patients: it is all about the dosing.
    Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
    Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
    Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
    J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
    J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.
    Minar P; Saeed SA; Afreen M; Kim MO; Denson LA
    J Pediatr Gastroenterol Nutr; 2016 May; 62(5):715-22. PubMed ID: 26551317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.